Core B: Clinical

核心 B：临床

• 批准号: 9066071
• 负责人: MARILYN S. ALBERT
• 金额: $ 104.4万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9066071
• 关键词: Autopsy; Biological Markers; Blood; Cerebrospinal Fluid; Clinical; Clinical assessments; Cognitive; Collection; Data; Data Analyses; Enrollment; Funding; Holidays; Impaired cognition; Individual; MRI Scans; Participant; Pattern; Persons; Pittsburgh Compound-B; Play; Positron; Positron-Emission Tomography; Procedures; Research Personnel; Role; Scanning; Schedule; Spinal Puncture; Update; Visit; Work; abstracting; clinical biomarkers; cognitive testing; cohort; data sharing; meetings; pre-clinical; predictive marker; tomography; web site

CLINICAL CORE - CORE B: ABSTRACT The Clinical Core (Core B) plays a pivotal role in the BIOCARD Study. The Clinical Core is responsible for: (1) the re-enrollment of BIOCARD subjects, (2) scheduling subjects for all visits and all study procedures (including clinical/cognitive assessments, lumbar punctures for collection of cerebrospinal fluid, magnetic resonance imaging (MRI) scans, and positron emission tomography scans using Pittsburgh compound B (PiB/PET scans), (3) completion of annual clinical and cognitive assessments, (4) acquisition of ante-mortem autopsy approval, (5) implementation of subject retention activities, (6) analyses of clinical and cognitive data concerning the study participants, (7) working collaboratively with the other Cores to examine combinations of biomarkers that are predictive of progression and to examine the order and pattern of biomarker change during preclinical AD, and (8) sharing of clinical and cognitive data with investigators in the field via the BIOCARD website, using the approved BIOCARD Study data sharing procedures.

临床核心 - 核心B：摘要 临床核心（核心B）在生物卡研究中起关键作用。临床核心负责：（1） 重新注册生物卡受试者，（2）所有访问和所有研究程序的调度受试者 （包括临床/认知评估，收集脑脊液的腰椎穿刺，磁性 共振成像（MRI）扫描和使用匹兹堡化合物B的正电子发射断层扫描B （PIB/PET扫描），（3）年度临床和认知评估的完成，（4）获取Ante-Mortem 尸检批准，（5）实施受试者保留活动，（6）临床和认知数据的分析 关于研究参与者，（7）与其他核心合作，检查 可以预测进展并检查生物标志物变化的顺序和模式的生物标志物 临床前AD和（8）通过Biocard与现场研究人员共享临床和认知数据 网站，使用批准的生物卡研究数据共享程序。